M&As this week: Shilpa Medicare, Charles River Labs, Mercal Capital

30th June 2016 (Last Updated June 30th, 2016 18:30)

Active pharmaceutical ingredient manufacturer Shilpa Medicare plans to merge with Navya Biologicals Private Limited, a company engaged in biologics and biosimilars R&D.

Active pharmaceutical ingredient manufacturer Shilpa Medicare plans to merge with Navya Biologicals Private Limited, a company engaged in biologics and biosimilars R&D.

The merger enables both companies to further advance biosimilars development and product process technologies.

Charles River Labs plans to enhance its Biologic Testing Solutions business abilities through the acquisition of Blue Stream Laboratories.

Pursuant to the acquisition, Charles River Labs and Blue Stream Labs will club their biologics capabilities to advance the development of biologics and biosimilar.

Mercal Capital Corporation, a capital pool company, has announced that it will acquire Folia Biotech INC., a clinical stage biopharmaceutical company.

According to the agreement, Mercal plans to acquire all the issued and outstanding shares of Folia by way of securities exchange of its common shares.